Pre-seed round · open

$2.5M.
SEIS / EIS eligible.

Raising to build the native AI stack, scale the two live products globally, and ship the wedge product. SEIS/EIS-eligible for UK-taxpaying investors via Advanced Subscription. International investors via SAFE on the same terms.

Round size
$2.5M
Pre-seed · SEIS / EIS eligible
Live products
2
MHRA Class I · 250+ active clinicians
Combined TAM 2028
$290B+
Across twelve verified market segments
Founder capital
Bootstrapped
Self-funded by the founder to date
Why now

The next 18 months decide the winner.

01 · foundation open

Open-weight models caught up to proprietary.

The defensible IP is now the corpus and the training — not the base model. The window to compile a proprietary medical reasoning layer is open.

02 · regulation ready

Most products are Non-Device CDS in the US.

MHRA Class I in hand. FDA January 2026 guidance enables the bulk of the roadmap without submission. EU MDR, FDA De Novo and APAC pathways sequenced for the one true device.

03 · clinician demand

250+ clinicians · zero marketing.

Physicians actively pulling the product. PLG traction exists. The next 18 months decide which ecosystem becomes the default.

Investment highlights

Why GacruxAI is differentiated.

Deployed, not pitched

  • ClinixSummary live with 250+ paying clinicians across multiple countries
  • ClinixQM live with a sovereign-deployment story
  • MHRA Class I · ISO 13485-aligned · SEIS/EIS Advance Assurance granted
  • Proven shipping cadence — no decks-only risk

Compounding moat

  • One backbone · fifteen interconnected products · same reasoning
  • Trained weights plus the proprietary corpus — 3–5 year reproduction lead
  • Marginal cost of the next product approaches zero
  • Single-product copying doesn't replicate the ecosystem

Stacked revenue model

  • Clinicians, enterprise health systems, medical schools, pharma R&D
  • Same accounts, multiple complementary revenue lines
  • A single pharma engagement matches thousands of clinician subscriptions
  • Non-device CDS pathway opens the US from Y1H2

Founder-market fit

  • Practising physician built the live product end-to-end
  • Technical leadership in healthcare data infra and AI integration
  • Commercial leadership with prior startup growth and pharma BD relationships
  • Clinical Safety Officer in seat from day one
Data room available on request

Talk to the founder.

Full financial model, TAM-bottom-up, use of funds, architecture detail, competitive teardown and customer references — all in the data room. Access on request to verified investors.

Request data room access Schedule a call